CB-010, a CRISPR-edited Allogeneic Anti-CD19 Car -T Cell Therapy with a PD-1 Knock Out, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

CB-010 - Caribou Biosci

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

https://www.eventscribe.net/2022/PPLC2022//ajaxcalls/PosterInfo.asp?efp=T0pMR0lPUU0xNzA0MA&PosterID=498952&rnd=0.9495566

Loretta J. Nastoupil1; Susan O'Brien2; Houston E. Holmes3; Ly Dsouza1; Doug Hart4; Emiri Matsuda5; Tarah SatterfieldLedbetter6; Justin Skoble7; Elizabeth Garner7; Mara Bryan7; Steven Kanner7; Ella Li8; Syed Rizvi7; and James Essell9

Jul 24, 2022